PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Clinical trials for PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Platinum-Resistant ovarian cancer: targeted drug combo enters phase 2 trial
Disease control OngoingThis phase 2 trial tests whether combining bevacizumab (a drug that blocks blood vessel growth) with anetumab ravtansine (a targeted therapy) works better than standard paclitaxel chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that no longer res…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Virus therapy takes on Platinum-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a c…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Triple-Drug cocktail shows promise for Tough-to-Treat recurrent cancers
Disease control OngoingThis study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…
Matched conditions: PLATINUM-RESISTANT PRIMARY PERITONEAL CARCINOMA
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC